DGIdb - AZACITIDINE Drug Record

AZACITIDINE chembl:CHEMBL1489 ApprovedAntineoplasticImmunotherapy

Alternate Names:

NSC-102816
VIDAZA
AZACITIDINE
LADAKAMYCIN
U-18496
AZACITIDINUM
5-AZAC
AZACYTIDINE
4-AMINO-1-BETA-D-RIBOFURANOSYL-S-TRIAZIN-2(1H)-ONE
AZACITIDINA
5-AZACYTIDINE
VIDAZA®
5 AZC
pubchem.substance:46509032
rxcui:1251
drugbank:00928
chemidplus:320-67-2
pubchem.compound:9444
chembl:CHEMBL1489

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Drug Class	antineoplastic agents
Year of Approval	2004
Drug Categories	drugs that are mainly renally excreted
Drug Categories	nucleic acid synthesis inhibitors
Drug Categories	nucleoside metabolic inhibitor

(8 More Sources)

Publications:

Baiocchi et al., 2003, 5-azacytidine reactivates the erythroid differentiation potential of the myeloid-restricted murine cell line 32D Ro., Exp. Cell Res.
Fenaux, 2005, Inhibitors of DNA methylation: beyond myelodysplastic syndromes., Nat Clin Pract Oncol
Kaminskas et al., 2005, FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension., Oncologist
Ghoshal et al., 2007, DNA methyltransferases as targets for cancer therapy., Drugs Today
Leone et al., 2003, Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS., Clin. Immunol.
Silverman et al., 2002, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B., J. Clin. Oncol.
Hollenbach et al., 2010, A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines., PLoS ONE
Silverman, 2001, Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS)., Oncologist
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Glover et al., 1987, Biochemistry of azacitidine: a review., Cancer Treat Rep
O'Dwyer et al., 2008, Azacitidine and the beginnings of therapeutic epigenetic modulation., Expert Opin Pharmacother
Cataldo et al., 2009, Azacitidine for the treatment of myelodysplastic syndrome., Expert Rev Anticancer Ther
Creusot et al., 1982, Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine., J. Biol. Chem.
Lin et al., 2001, GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells., Am. J. Pathol.
Bejar et al., 2014, TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients., Blood
Itzykson et al., 2011, Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias., Leukemia
López-Karpovitch et al., 2002, Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin m, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia., Cytokine
Kato et al., 2003, Expression of pericyte, mesangium and muscle markers in malignant rhabdoid tumor cell lines: differentiation-induction using 5-azacytidine., Cancer Sci.
Avvedimento et al., 1989, Reactivation of thyroglobulin gene expression in transformed thyroid cells by 5-azacytidine., Cell
el Yaagoubi et al., 1998, 5-Azacytidine modulates gamma-glutamyltransferase and glutathione levels in two human prostatic adenocarcinoma cell lines., Biochem. Mol. Biol. Int.
von Wronski et al., 1994, Effect of 5-azacytidine on expression of the human DNA repair enzyme O6-methylguanine-DNA methyltransferase., Carcinogenesis
Januchowski et al., 2005, Effect of 5-azacytidine and procainamide on CD3-zeta chain expression in Jurkat T cells., Biomed. Pharmacother.
Ravandi et al., 2013, Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation., Blood
Strati et al., 2015, Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome., Am. J. Hematol.
Hsiao et al., 1996, Comparison of transformation by manganese sulfate and 5-azacytidine in Rat 6 cells overexpressing the c-myc oncogene., Carcinogenesis
Visani G et al., 2018, MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine., Pharmacogenomics J
John et al., 1989, Extensive changes in DNA methylation patterns accompany activation of a silent T-DNA ipt gene in Agrobacterium tumefaciens-transformed plant cells., Mol. Cell. Biol.
Xing et al., 1999, Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation., Int. J. Cancer
Borodovsky et al., 2013, 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft., Oncotarget
Cook et al., 1983, Effect of 5-azacytidine on rat liver alpha-fetoprotein gene expression., Biochem. Biophys. Res. Commun.
Fanciullino R et al., 2015, Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome., Pharmacogenet Genomics
del Senno et al., 1986, Methylation and expression of c-myc and c-abl oncogenes in human leukemic K562 cells before and after treatment with 5-azacytidine., Cancer Detect. Prev.

AZACITIDINE TRIT1

Interaction Score: 3.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2479825

Sources:
NCI
AZACITIDINE ASXL1

Interaction Score: 1.67

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

Response Type sensitive

Approval Status Clinical Study

PMIDs:
25224413

Sources:
JAX-CKB
AZACITIDINE TAGLN

Interaction Score: 1.67

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14662021

Sources:
NCI
AZACITIDINE TET2

Interaction Score: 1.67

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Clinical Study

Response Type sensitive

Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

PMIDs:
25224413 21494260

Sources:
JAX-CKB
AZACITIDINE CD247

Interaction Score: 1.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15795105

Sources:
NCI
AZACITIDINE DNMT1

Interaction Score: 0.97

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name azacitidine,Vidaza

Novel drug target Established target

Mechanism of Interaction DNA (cytosine-5)-methyltransferase 1 inhibitor

PMIDs:
16341239 15793220 17612710 14585280 12011120 20126405 11700387 11752352 2443243 18627335 19589026 6173384

Sources:
DrugBank TdgClinicalTrial ChemblInteractions NCI TEND TTD
AZACITIDINE GATA2

Interaction Score: 0.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12706120

Sources:
NCI
AZACITIDINE CDA

Interaction Score: 0.56

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25850965

Sources:
PharmGKB
AZACITIDINE IL11

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12543079

Sources:
NCI
AZACITIDINE LIF

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12543079

Sources:
NCI
AZACITIDINE DNMT3A

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction DNA (cytosine-5)-methyltransferase 3A inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
AZACITIDINE AFP

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6197072

Sources:
NCI
AZACITIDINE TG

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2476239

Sources:
NCI
AZACITIDINE GGT1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9801800

Sources:
NCI
AZACITIDINE MGMT

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7511991

Sources:
NCI
AZACITIDINE MYC

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9006118

Sources:
NCI
AZACITIDINE TYMS

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29205204

Sources:
PharmGKB
AZACITIDINE PLAU

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10209960

Sources:
NCI
AZACITIDINE FLT3

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy Azacitidine + Midostaurin

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

PMIDs:
23613521 25530214

Sources:
JAX-CKB MyCancerGenomeClinicalTrial
AZACITIDINE GSTP1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11696442

Sources:
NCI
AZACITIDINE ABL1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2425967

Sources:
NCI
AZACITIDINE HBB

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE THPO

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE RORC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE IDH1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type grade III astrocytoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
24077805

Sources:
DTC JAX-CKB
AZACITIDINE NR3C1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE HTT

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE SMAD3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE ATAD5

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE TP53

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE ALDH1A1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE GMNN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZACITIDINE AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB00928

Version: 5.1.7

Alternate Names:

AZACITIDINE DrugBank Drug Name

320-67-2 CAS Number

Azacitidine Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Kaminskas et al., 2005, FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension., Oncologist

Hollenbach et al., 2010, A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines., PLoS ONE

Glover et al., 1987, Biochemistry of azacitidine: a review., Cancer Treat Rep

TEND: AZACITIDINE
- Version: 01-August-2011
Alternate Names:

AZACITIDINE Primary Drug Name

Drug Info:

Year of Approval 2004

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: AZACITIDINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: AZACYTIDINE

Version: 14-September-2017

Alternate Names:

C288 NCI drug code

Drug Info:

Publications:

López-Karpovitch et al., 2002, Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin m, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia., Cytokine

Xing et al., 1999, Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation., Int. J. Cancer

NCI: 5-AZACYTIDINE

Version: 14-September-2017

Alternate Names:

C288 NCI drug code

Drug Info:

Publications:

Avvedimento et al., 1989, Reactivation of thyroglobulin gene expression in transformed thyroid cells by 5-azacytidine., Cell

del Senno et al., 1986, Methylation and expression of c-myc and c-abl oncogenes in human leukemic K562 cells before and after treatment with 5-azacytidine., Cancer Detect. Prev.

Creusot et al., 1982, Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine., J. Biol. Chem.

PharmGKB: azacitidine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Visani G et al., 2018, MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine., Pharmacogenomics J

Fanciullino R et al., 2015, Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome., Pharmacogenet Genomics

JAX-CKB: Azacitidine

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Strati et al., 2015, Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome., Am. J. Hematol.

Ravandi et al., 2013, Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation., Blood

Borodovsky et al., 2013, 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft., Oncotarget

TTD: Azacitidine
- Version: 2020.06.01
Alternate Names:

D09FAZ TTD Drug ID

Drug Info:

Publications:
DTC: AZACITIDINE
- Version: 02-September-2020
Alternate Names:

CHEMBL1489 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1489
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: AZACITIDINE
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1489
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	myelodysplastic/myeloproliferative neoplasm
Response Type	sensitive
Approval Status	Clinical Study

Trial Name	azacitidine,Vidaza
Novel drug target	Established target
Mechanism of Interaction	DNA (cytosine-5)-methyltransferase 1 inhibitor

Mechanism of Interaction	DNA (cytosine-5)-methyltransferase 3A inhibitor
Direct Interaction	yes

combination therapy	Azacitidine + Midostaurin
Indication/Tumor Type	acute myeloid leukemia
Response Type	sensitive

Indication/Tumor Type	grade III astrocytoma
Response Type	sensitive
Approval Status	Preclinical

AZACITIDINE	DrugBank Drug Name
320-67-2	CAS Number
Azacitidine	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

AZACITIDINE Drug Record

AZACITIDINE chembl:CHEMBL1489 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2479825

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm Response Type sensitive Approval Status Clinical Study

PMIDs: 25224413

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14662021

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Approval Status Clinical Study Response Type sensitive Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

PMIDs: 25224413 21494260

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15795105

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name azacitidine,Vidaza Novel drug target Established target Mechanism of Interaction DNA (cytosine-5)-methyltransferase 1 inhibitor

PMIDs: 16341239 15793220 17612710 14585280 12011120 20126405 11700387 11752352 2443243 18627335 19589026 6173384

Sources: DrugBank TdgClinicalTrial ChemblInteractions NCI TEND TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12706120

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25850965

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12543079

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12543079

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction DNA (cytosine-5)-methyltransferase 3A inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6197072

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2476239

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9801800

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7511991

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9006118

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29205204

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10209960

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: combination therapy Azacitidine + Midostaurin Indication/Tumor Type acute myeloid leukemia Response Type sensitive

PMIDs: 23613521 25530214

Interaction Types & Directionality:

n/a

PMIDs:
2479825

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

Response Type sensitive

Approval Status Clinical Study

PMIDs:
25224413

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
14662021

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Clinical Study

Response Type sensitive

Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

PMIDs:
25224413 21494260

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
15795105

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name azacitidine,Vidaza

Novel drug target Established target

Mechanism of Interaction DNA (cytosine-5)-methyltransferase 1 inhibitor

PMIDs:
16341239 15793220 17612710 14585280 12011120 20126405 11700387 11752352 2443243 18627335 19589026 6173384

Sources:
DrugBank TdgClinicalTrial ChemblInteractions NCI TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
12706120

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25850965

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12543079

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12543079

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction DNA (cytosine-5)-methyltransferase 3A inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
6197072

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
2476239

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9801800

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7511991

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9006118

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
29205204

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10209960

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy Azacitidine + Midostaurin

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

PMIDs:
23613521 25530214

Sources:
JAX-CKB MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
11696442

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
2425967

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type grade III astrocytoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
24077805